摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

sodium 5-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethoxy)-8-methyl-2-(3-methyl-1-benzofuran-2-yl)quinoline-4-carboxylate | 2095064-06-3

中文名称
——
中文别名
——
英文名称
sodium 5-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethoxy)-8-methyl-2-(3-methyl-1-benzofuran-2-yl)quinoline-4-carboxylate
英文别名
Posenacaftor sodium;sodium;8-methyl-2-(3-methyl-1-benzofuran-2-yl)-5-[(1R)-1-(oxan-4-yl)ethoxy]quinoline-4-carboxylate
sodium 5-((1R)-1-(tetrahydro-2H-pyran-4-yl)ethoxy)-8-methyl-2-(3-methyl-1-benzofuran-2-yl)quinoline-4-carboxylate化学式
CAS
2095064-06-3
化学式
C27H26NO5*Na
mdl
——
分子量
467.497
InChiKey
FIMNRWQYZVDFTK-UNTBIKODSA-M
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 溶解度:
    DMSO:200 mg/mL(427.82 mM;需要超声波)

计算性质

  • 辛醇/水分配系数(LogP):
    1.83
  • 重原子数:
    34
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    84.6
  • 氢给体数:
    0
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR INCREASING CFTR ACTIVITY<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES POUR AUGMENTER L'ACTIVITÉ DE CFTR
    申请人:PROTEOSTASIS THERAPEUTICS INC
    公开号:WO2019071078A1
    公开(公告)日:2019-04-11
    The present disclosure features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of compounds disclosed herein.
    本公开涉及治疗与CFTR活性降低有关的病症或与蛋白质稳态失调有关的病症的方法,包括向受试者施用本文所披露的化合物的有效量。
  • Compounds, compositions, and methods for modulating CFTR
    申请人:Proteostasis Therapeutics, Inc.
    公开号:US10550106B2
    公开(公告)日:2020-02-04
    The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
    本公开涉及所公开的化合物,这些化合物可以调节,例如,解决细胞处理 CFTR 活性的潜在缺陷。
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR
    申请人:Proteostasis Therapeutics, Inc.
    公开号:EP3359536B1
    公开(公告)日:2021-08-04
  • COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY
    申请人:Proteostasis Therapeutics, Inc.
    公开号:US20190248765A1
    公开(公告)日:2019-08-15
    The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
  • N-PHENYL-2-(3-PHENYL-6-OXO-1,6-DIHYDROPYRIDAZIN-1-YL)ACETAMIDE DERIVATIVES FOR TREATING CYSTIC FIBROSIS
    申请人:Proteostasis Therapeutics, Inc.
    公开号:US20190256474A1
    公开(公告)日:2019-08-22
    The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.
查看更多